https://mindmedicinelaw.com/briefing/heidi-overton-s-fda-nomination-and-psychedelics-policy-20260828-36531The Psychedelic Journalen2026-08-28T22:02:47.530481+00:00Heidi Overton's FDA Nomination and Psychedelics PolicyHeidi Overton, FDA nomination, psychedelic policy, 4-OH-DiPT, psychedelic research, drug regulation, clinical trials, market dynamicshttps://mindmedicinelaw.com/briefing/challenge-to-psilocybin-ballot-measure-in-joseph-oregon-20260828-36375The Psychedelic Journalen2026-08-28T15:07:16.608250+00:00Challenge to Psilocybin Ballot Measure in Joseph, Oregonpsilocybin regulation, Joseph Oregon, legal challenge, ballot measure, psychedelic policy, community debate, Oregon Measure 109, local jurisdiction, therapeutic use, public safetyhttps://mindmedicinelaw.com/briefing/tampa-bay-expands-ketamine-access-for-veterans-with-ptsd-20260828-36374The Psychedelic Journalen2026-08-28T15:06:16.046402+00:00Tampa Bay Expands Ketamine Access for Veterans with PTSDketamine therapy, PTSD treatment, veterans mental health, Tampa Bay, psychedelic-assisted therapy, mental health policy, glutamate modulation, psychedelic research, clinical trials, public health initiativeshttps://mindmedicinelaw.com/briefing/psilocybin-in-treatment-resistant-depression-emerging-evidence-20260827-36576The Psychedelic Journalen2026-08-29T15:05:11.596575+00:00Psilocybin in Treatment-Resistant Depression: Emerging Evidencepsilocybin, treatment-resistant depression, psychedelic therapy, ketamine, clinical trials, FDA, neuroscience, mental health, serotonin receptors, psychiatric carehttps://mindmedicinelaw.com/briefing/japanese-versions-of-meq-4-and-ceq-7-enhance-psychedelic-research-20260827-36580The Psychedelic Journalen2026-08-29T15:05:01.359080+00:00Japanese Versions of MEQ-4 and CEQ-7 Enhance Psychedelic ResearchJapanese MEQ-4, Japanese CEQ-7, psychedelic research Japan, mystical experiences, challenging experiences, questionnaire translation, cultural adaptation, psychedelic studies, therapeutic applications, cross-cultural researchhttps://mindmedicinelaw.com/briefing/psilocybin-enhances-sociability-in-asd-mice-without-wakefulness-20260827-36579The Psychedelic Journalen2026-08-29T15:04:45.424875+00:00Psilocybin Enhances Sociability in ASD Mice Without Wakefulnesspsilocybin, autism spectrum disorder, sociability, psychedelic therapy, serotonin receptors, neuropsychiatric conditions, clinical trials, therapeutic benefits, psychedelic effects, mouse modelhttps://mindmedicinelaw.com/briefing/ayahuasca-s-impact-on-depression-insights-from-las-vegas-study-20260827-36577The Psychedelic Journalen2026-08-29T15:04:35.016053+00:00Ayahuasca's Impact on Depression: Insights from Las Vegas Studyayahuasca, depression, prospective cohort study, Las Vegas, mental health, naturalistic use, PHQ-9, psychedelic research, observational studyhttps://mindmedicinelaw.com/briefing/beta-oscillatory-brain-state-post-psychedelic-use-insights-and-implications-20260827-36622The Psychedelic Journalen2026-08-29T15:04:24.849264+00:00Beta Oscillatory Brain State Post-Psychedelic Use: Insights and Implicationsbeta oscillatory brain state, psilocybin, 5-MeO-DMT, neural signature, psychedelic research, therapeutic applications, EEG, brain function, psychiatric treatment, biomarkershttps://mindmedicinelaw.com/briefing/ketamine-s-potential-in-treating-ocd-a-systematic-review-20260827-36513The Psychedelic Journalen2026-08-28T22:03:04.256755+00:00Ketamine's Potential in Treating OCD: A Systematic Reviewketamine, obsessive-compulsive disorder, OCD treatment, clinical guidelines, psychedelic research, mental health, NMDA receptor, glutamate neurotransmission, treatment protocols, systematic reviewhttps://mindmedicinelaw.com/briefing/olfm1-gene-hypomethylation-a-new-biomarker-for-depression-20260827-36308The Psychedelic Journalen2026-08-28T15:07:35.315543+00:00OLFM1 Gene Hypomethylation: A New Biomarker for DepressionOLFM1 gene, hypomethylation, depression biomarker, epigenetics, psychedelic research, genetic markers, mental health, DNA methylation, psychiatric disorders, personalized medicinehttps://mindmedicinelaw.com/briefing/psilocybin-for-trd-amcp-panel-insights-and-implications-20260827-36262The Psychedelic Journalen2026-08-28T15:06:30.325427+00:00Psilocybin for TRD: AMCP Panel Insights and Implicationspsilocybin, treatment-resistant depression, AMCP panel, managed care, mental health, clinical trials, payer decisions, health policy, psychedelic therapy, healthcare networkhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-service-centers-safety-and-cost-challenges-20260827-36263The Psychedelic Journalen2026-08-28T15:05:59.477403+00:00Oregon's Psilocybin Service Centers: Safety and Cost ChallengesOregon psilocybin service centers, psychiatric assessment, psilocybin safety protocols, financial barriers in psilocybin services, psilocybin accessibility, psilocybin policy implications, psilocybin service model, psilocybin therapy costs, psilocybin research, psilocybin legal frameworkhttps://mindmedicinelaw.com/briefing/bdnf-trkb-mtor-axis-and-depression-new-insights-20260826-36309The Psychedelic Journalen2026-08-28T15:08:11.872894+00:00BDNF–TrkB–mTOR Axis and Depression: New InsightsBDNF, TrkB, mTOR, depression, neuroinflammation, oxidative stress, neurotrophic factors, psychiatric treatment, mental health, biomarkershttps://mindmedicinelaw.com/briefing/ipsc-derived-models-psychiatry-insights-challenges-20260826-36312The Psychedelic Journalen2026-08-28T15:07:54.804270+00:00iPSC-Derived Models: Psychiatry Insights & ChallengesiPSC-derived models, psychiatric disorders, precision psychiatry, genetic risks, neural differentiation, patient stratification, functional phenotyping, translational research, polygenic architecture, ethical considerationshttps://mindmedicinelaw.com/briefing/ketamine-in-treating-resistant-depression-efficacy-and-risks-20260826-36313The Psychedelic Journalen2026-08-28T15:06:51.312968+00:00Ketamine in Treating Resistant Depression: Efficacy and Risksketamine, treatment-resistant depression, esketamine, rapid-acting antidepressants, glutamatergic neurotransmission, clinical trials, FDA approval, adverse effects, long-term safety, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/stress-substance-use-and-brain-white-matter-new-insights-20260825-36158The Psychedelic Journalen2026-08-28T15:08:30.774128+00:00Stress, Substance Use, and Brain White Matter: New Insightsstress hormones, substance use disorder, brain white matter, cortisol response, longitudinal study, biomarkers, substance use involvement, white matter microstructure, cingulum, youth interventionhttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-in-post-op-pain-new-insights-20260818-36662The Psychedelic Journalen2026-08-29T15:04:52.810594+00:00Ketamine and Esketamine in Post-Op Pain: New Insightsketamine, esketamine, postoperative pain, gynecological surgery, analgesia, clinical trials, pain management, opioid alternatives, NMDA receptor antagonists, psychedelics